PROK PROK
Company Profile ↓Company Overview
PROK (PROK) is a publicly traded company listed on with a market capitalization of $236.82M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $893.00K (+1075.0% YoY); net profit $-68.99M.
- Trailing 12 Months Year-on-year growth — revenue +1075.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 1,075.00% |
Stock Price Performance
| 1 Year: | -48.77% |
| 6 Months: | -17.73% |
| 3 Months: | -13.02% |
| 1 Month: | -14.36% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)52.43 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 49.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 230.00K | 221.00K | 217.00K | 225.00K | 226.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 41.62M | 39.93M | 38.76M | 45.60M | 45.16M |
| Operating Income | -143 | -17.08M | -66.46M | -20.74M | -35.57M | -40.88M | -39.82M | -46.62M | -40.08M | -43.06M | -48.97M | -41.39M | -39.71M | -38.54M | -45.37M | -44.93M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | -35.76M | -34.65M | -33.61M | -40.60M | -40.95M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | 0 | 1.00K | 2.00K | 1.00K | 15.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | -37.36M | -36.12M | -35.28M | -42.44M | -42.62M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | 591.00K | 848.00K | 560.00K | -1.58M | 0 |
| Net Income | -143 | -252.49K | -3.98M | -2.27M | -29.93M | -9.66M | -9.12M | -10.98M | -9.49M | -12.51M | -17.91M | -16.73M | -16.55M | -16.47M | -19.23M | -20.04M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -0.13 | -0.13 | -0.12 | - | -0.14 |
| R&D Expense | - | 14.74M | 28.49M | 11.56M | 21.13M | 25.62M | 26.36M | 32.20M | 27.23M | 29.40M | 31.25M | 27.26M | 25.88M | 26.82M | - | 33.84M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 76.00K | 893.00K |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 153.01M | 151.52M | 183.75M | 165.90M |
| Operating Income | -27.02M | -55.11M | -153.01M | -151.52M | -183.68M | -165.01M |
| EBITDA | - | - | -143.99M | -125.59M | -158.49M | -144.62M |
| Interest Expense | - | - | 215.00K | 12.00K | 9.00K | 4.00K |
| Pretax Income | - | - | -147.24M | -129.45M | -163.93M | -151.20M |
| Tax Provision | - | - | 896.00K | 6.00M | -598.00K | 414.00K |
| Net Income | - | -55.15M | -108.03M | -35.47M | -61.19M | -68.99M |
| Diluted EPS | - | - | -0.23 | -0.57 | -0.62 | -0.52 |
| R&D Expense | 21.04M | 46.26M | 82.07M | 106.71M | 127.67M | 114.12M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Feb 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | 518.00M | 420.55M | 441.07M | 335.57M |
| Current Assets | - | - | - | - | 504.72M | 374.15M | 395.88M | 280.68M |
| Cash & Equivalents | - | - | - | - | 490.25M | 60.65M | 99.12M | 108.54M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 0 | 1.38M | 2.45M | 1.13M |
| Total Liabilities | - | - | - | - | 13.06M | 29.22M | 39.44M | 34.78M |
| Current Liabilities | - | - | - | - | 10.87M | 25.04M | 36.22M | 30.74M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 2.40M | 4.41M | 3.24M | 4.04M |
| Total Equity | 15.88M | 9.86M | 0 | - | -1.10B | -1.10B | -994.95M | -1.01B |
| Shares Outstanding | - | - | - | - | 61.54M | 59.88M | 128.05M | 141.81M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -25.18M | - | -77.09M | -90.07M | -126.35M | -120.12M |
| Investing Cash Flow | -5.46M | - | -1.74M | -329.98M | 20.41M | 103.97M |
| Financing Cash Flow | 19.99M | - | 548.52M | -9.55M | 144.41M | 25.57M |
| Capital Expenditure | -5.46M | - | -1.85M | -34.20M | -29.51M | -15.20M |
| Free Cash Flow | -30.64M | - | -78.94M | -124.27M | -155.86M | -135.31M |
| Net Change in Cash | - | - | 469.69M | -429.60M | 38.47M | 9.42M |
| Share Buybacks | - | 0 | 0 | 9.50M | 0 | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -241,678.9% | -18,477.8% |
| Net Margin % | - | - | - | - | -80,507.9% | -7,725.2% |
| ROE % | - | - | 9.9% | 3.2% | 6.1% | 6.8% |
| ROCE % | - | - | -30.2% | -38.3% | -45.4% | -54.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PROK
Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path
ProKidney Corp. (NASDAQ:PROK) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main story centers on rilparencel, its experimental cell therapy for patients with advanced chronic kidney disease and type 2 di…
Identiv And Two Other Penny Stocks To Watch Closely
The market remained flat over the last week, but it is up 26% over the past year, with earnings forecast to grow by 16% annually. For investors willing to look beyond the big names, penny stocks can present intriguing opportunities for grow…
ProKidney Appoints Kenneth Locke as Chief Technical Officer
Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencelWINST…
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
PROKIDNEY CP (PROK) delivered earnings and revenue surprises of -7.69% and +222.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027Peer-reviewed results from the Phase 2 REGEN-007 study were published in the Cli…
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -15.09% and +2.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?…
PROK — Frequently Asked Questions
What is the current share price of PROK?
As of 2026-08-05 17:25 PDT, PROK trades at $1.67 on NASDAQ/NYSE. Its 52-week range is $1.50 to $3.30.
What is the market capitalisation of PROK?
PROK has a market capitalisation of $236.82M on NASDAQ/NYSE.
What is the P/E ratio of PROK?
PROK trades at a trailing price-to-earnings (P/E) ratio of -3.21. Its price-to-book (P/B) ratio is -0.23.
What is the return on equity (ROE) of PROK?
PROK has a return on equity (ROE) of 6.82%. Its return on capital employed (ROCE) is -54.13%.
Is PROK a good stock to buy?
This page provides a data-driven analysis of PROK, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.